BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics firm focused on early cancer detection, is pleased to support Colorectal Cancer Awareness Month this March. Early detection of colorectal cancer (CRC) greatly increases survival rates, making awareness and proactive screening vital in combating this disease. CRC is the second leading cause of cancer deaths worldwide, causing over 930,000 deaths annually. In the U.S., it is estimated that over 150,000 people were diagnosed with colorectal cancer, while in Germany, approximately 22,836 people die from CRC each year, representing a significant portion of cancer-related deaths in the country.

Mainz Biomed is dedicated to fighting CRC by developing diagnostic solutions that prioritize early intervention. Through ongoing research, the Company seeks to transform CRC management with its next-generation product, which will enable early detection of pre-cancerous adenomas to enhance prevention strategies. Mainz Biomed’s combined analysis of the ColoFuture and eAArly DETECT studies, utilizing mRNA biomarkers, the FIT test, and a proprietary AI algorithm, demonstrated an impressive 82% sensitivity in detecting advanced adenomas and 97% specificity. These results emphasize the significant potential for early intervention and reinforce the Company’s goal of creating advanced screening methods to improve patient outcomes and promote more effective prevention strategies in the future.

Mainz Biomed, with its current flagship product, ColoAlert®, is improving CRC screening by expanding collaborations with laboratories, including a recent partnership in Switzerland. These partnerships enable the company to make high-quality, DNA-based screening more accessible.

Reducing barriers to CRC screening is essential for empowering patients and healthcare professionals in early cancer detection. A key strategy is increasing accessibility through at-home testing options, now available via a web-based platform through one of Mainz Biomed’s laboratory partners, European Oncology Lab.

Colorectal Cancer Awareness Month is an important reminder that early detection can save lives. Despite being one of the most preventable cancers, CRC remains a leading cause of cancer-related deaths globally due to inadequate screening participation. Mainz Biomed is dedicated to changing this by increasing awareness, broadening access to innovative screening solutions, and encouraging individuals to proactively manage their health. By promoting education, innovation, and accessibility, the Company continues to advocate for a future where colorectal cancer is detected early and, ultimately, prevented.

Please follow us to stay up to date:

About Mainz Biomed NV
Mainz Biomed develops molecular genetic diagnostic solutions for life-threatening diseases that are ready for the market. ColoAlert®, the Company’s main product, is a precise, non-invasive, and user-friendly diagnostic test for the early detection of colorectal cancer. ColoAlert® is sold throughout Europe and the United Arab Emirates. The Company is currently conducting a crucial clinical study for FDA approval in the US. Mainz Biomed’s product pipeline also features PancAlert, an early-stage screening test for pancreatic cancer that uses real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. For more information, visit or follow us on , and .

For media inquiries
MC Services AG
Anne Hennecke / Simone Neeten
+49 211 529252 17

For investor inquiries, please contact

Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995’s “safe harbor” provisions. These forward-looking statements can be identified by terms like “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” as well as other similar expressions that predict or suggest future events or trends, or that are not statements of historical fact. These statements reflect the current analysis of available information and are subject to various risks and uncertainties. Therefore, caution should be exercised when relying on them. Actual results may differ significantly from the Company’s expectations or projections due to known and unknown risks. Factors that could cause actual results to differ materially include: (i) failure to achieve projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties detailed herein, as well as those discussed periodically in other reports and public filings made by the Company with the Securities and Exchange Commission (the “SEC”). Further information regarding these and other factors that may affect the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are publicly available on the SEC’s website at www.sec.gov. Any forward-looking statement in this press release is based solely on information currently available to Mainz Biomed and speaks only as of the date it is made. Mainz Biomed undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

“`